Tulip BioMed, formerly known as Cell Bio-Systems, a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it has filed for a provisional patent on its hydrophilic coating process, which affects the manufacturing and use of cannulae. Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=135644.%20)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Theradiag Snags CE Mark for Biotherapy Monitoring Analyzer
The i-Track10 can be integrated into laboratory automation systems and features random access analysis and continuous loading capabilities.
Petition Urges FDA, DEA to Classify Tramadol as a Schedule II Controlled Substance
The DEA classified tramadol as a Schedule IV controlled substance in 2014.
